A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

Key facts

Sponsor

Peking Union Medical College Hospital

Intervention

68Ga-TATE-RGD(drug)

Enrollment

40 enrolled

Eligibility

18-90 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07413796
  Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures
  Medical University of Warsaw
• RECRUITINGPHASE2NCT06955169
  Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
  RTOG Foundation, Inc.
• RECRUITINGPHASE1, PHASE2NCT07150806
  RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
  Joshua Palmer
• RECRUITINGNANCT06831461
  Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
  Tata Memorial Centre
• RECRUITINGNCT07044076
  Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas
  Centre Hospitalier St Anne
• RECRUITINGPHASE2NCT05940493
  Abemaciclib in Newly Diagnosed Meningioma Patients
  Nader Sanai
• RECRUITINGNCT06874426
  The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGPHASE2NCT06326190
  177Lu-DOTATATE for Recurrent Meningioma
  European Organisation for Research and Treatment of Cancer - EORTC

See all trials for Meningioma →